A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Non-Small Cell Lung Cancer|HER2-positive Colorectal Cancer|HER2-positive Tumors|HER2 Low Breast Cancer
Interventions: DRUG: XMT-2056
Sponsor: Mersana Therapeutics